These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9834471)

  • 1. [Recommendations for blood studies and clinical monitoring in early detection of valproate-associated liver failure. Results of a consensus conferences 9 May - 11 May 1997 in Berlin].
    König SA; Elger CE; Vassella F; Schmidt D; Bergmann A; Boenigk HE; Despland PA; Genton P; Krämer G; Löscher W; Mayer T; Nau H; Schneble H; Siemes H; Stefan H; Wolf P
    Nervenarzt; 1998 Oct; 69(10):835-40. PubMed ID: 9834471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities.
    König SA; Siemes H; Bläker F; Boenigk E; Gross-Selbeck G; Hanefeld F; Haas N; Köhler B; Koelfen W; Korinthenberg R
    Epilepsia; 1994; 35(5):1005-15. PubMed ID: 7925143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis.
    Huang YL; Hong HS; Wang ZW; Kuo TT
    J Am Acad Dermatol; 2003 Aug; 49(2):316-9. PubMed ID: 12894087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy.
    Wyllie E; Wyllie R
    Epilepsia; 1991; 32 Suppl 5():S74-9. PubMed ID: 1743173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure: a need for critical risk-benefit appraisal in the use of valproate.
    Thomson MA; Lynch S; Strong R; Shepherd RW; Marsh W
    Transplant Proc; 2000 Feb; 32(1):200-3. PubMed ID: 10701024
    [No Abstract]   [Full Text] [Related]  

  • 6. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003.
    Koenig SA; Buesing D; Longin E; Oehring R; Häussermann P; Kluger G; Lindmayer F; Hanusch R; Degen I; Kuhn H; Samii K; Jungck A; Brückner R; Seitz R; Boxtermann W; Weber Y; Knapp R; Richard HH; Weidner B; Kasper JM; Haensch CA; Fitzek S; Hartmann M; Borusiak P; Müller-Deile A; Degenhardt V; Korenke GC; Hoppen T; Specht U; Gerstner T
    Epilepsia; 2006 Dec; 47(12):2027-31. PubMed ID: 17201699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic-acid-induced thrombocytopenia and hepatotoxicity: discontinuation of treatment?
    Lackmann GM
    Pharmacology; 2004 Feb; 70(2):57-8. PubMed ID: 14685007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy.
    Hauser E; Seidl R; Freilinger M; Male C; Herkner K
    Brain Dev; 1996; 18(2):105-9. PubMed ID: 8733899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate hepatotoxicity: two new cases, a summary of others, and recommendations.
    Fenichel GM; Greene HL
    Pediatr Neurol; 1985; 1(2):109-13. PubMed ID: 3939742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of carnitine supplementation during valproic acid therapy.
    Raskind JY; El-Chaar GM
    Ann Pharmacother; 2000 May; 34(5):630-8. PubMed ID: 10852092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Laboratory parameters in valproate therapy].
    Schneble H
    Nervenarzt; 1982 Dec; 53(12):684-90. PubMed ID: 6818481
    [No Abstract]   [Full Text] [Related]  

  • 12. Valproic acid hepatic fatalities: a retrospective review.
    Dreifuss FE; Santilli N; Langer DH; Sweeney KP; Moline KA; Menander KB
    Neurology; 1987 Mar; 37(3):379-85. PubMed ID: 3102998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding topiramate to valproate therapy may cause reversible hepatic failure.
    Bumb A; Diederich N; Beyenburg S
    Epileptic Disord; 2003 Sep; 5(3):157-9. PubMed ID: 14684351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal liver failure in 16 children with valproate therapy.
    Scheffner D; König S; Rauterberg-Ruland I; Kochen W; Hofmann WJ; Unkelbach S
    Epilepsia; 1988; 29(5):530-42. PubMed ID: 3137017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thinking beyond the obvious: hepatotoxicity secondary to idiosyncratic depakote toxicity.
    Chaudrey KH; Naser TB; Steinberg A; Avashia KD; Nouri-Kolouri M; Asadi S; Irshad Khan SI; Ihsan M
    Am J Ther; 2012 Nov; 19(6):403-6. PubMed ID: 21248613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.
    Barrueto F; Hack JB
    Acad Emerg Med; 2001 Oct; 8(10):999-1001. PubMed ID: 11581089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
    Panda S; Radhakrishnan K
    J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate therapy for prevention of posttraumatic seizures: a randomized trial.
    Temkin NR; Dikmen SS; Anderson GD; Wilensky AJ; Holmes MD; Cohen W; Newell DW; Nelson P; Awan A; Winn HR
    J Neurosurg; 1999 Oct; 91(4):593-600. PubMed ID: 10507380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fatal hepatic necrosis during treatment with sodium valproate].
    Miguil M; Chlihi A; Mjahed K; Sarf I; Moutawakkil S; Benaguida M
    Cah Anesthesiol; 1995; 43(3):325-6. PubMed ID: 7583902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium valproate and hepatotoxicity in epileptics.
    Beran RG; Rischbieth RH
    Med J Aust; 1979 Dec; 2(11):603-4. PubMed ID: 119151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.